How many stocks are there of Diaceutics?
The current number of stocks of Diaceutics is 84.23 M undefined.
Diaceutics Stocks 2024
Diaceutics Stocks
84.23 M
Ticker
DXRX.L
ISIN
GB00BJQTGV64
WKN
A2PF80
In 2024, Diaceutics had 84.23 M outstanding stocks, a 0% change from the 84.23 M stocks in the previous year.
The Diaceutics Stocks history
| YEAR | NUMBER OF STOCKS (undefined GBP) |
|---|---|
| 2029e | 84.23 |
| 2028e | 84.23 |
| 2027e | 84.23 |
| 2026e | 84.23 |
| 2025e | 84.23 |
| 2024e | 84.23 |
| 2023 | 84.23 |
| 2022 | 86.09 |
| 2021 | 84.94 |
| 2020 | 77.83 |
| 2019 | 64.17 |
| 2018 | 69.58 |
| 2017 | 69.58 |
| 2016 | 69.58 |
Diaceutics shares outstanding GB00BJQTGV64 · A2PF80
The number of shares was Diaceutics in 2023 — This indicates how many shares 84.227 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Diaceutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Diaceutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Diaceutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Diaceutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2016 | 69.58 M Aktien |
| 2017 | 69.58 M Aktien |
| 2018 | 69.58 M Aktien |
| 2019 | 64.17 M Aktien |
| 2020 | 77.83 M Aktien |
| 2021 | 84.94 M Aktien |
| 2022 | 86.09 M Aktien |
| 2023 | 84.23 M Aktien |
| 2024e | 84.23 M Aktien |
| 2025e | 84.23 M Aktien |
| 2026e | 84.23 M Aktien |
| 2027e | 84.23 M Aktien |
| 2028e | 84.23 M Aktien |
| 2029e | 84.23 M Aktien |
Diaceutics Aktienanalyse
What does Diaceutics do?
Diaceutics PLC is a consulting company specializing in optimizing diagnostic and treatment solutions for patients with serious and complex diseases. It was founded in 2005 by Peter Keeling in Belfast, Northern Ireland, and is now headquartered in London, UK. The company is listed on the London Stock Exchange and has offices in Europe, Asia, North America, and Australia. The business model of Diaceutics is based on the increasing number of personalized medicines on the market, targeting specific genetic markers to enable more accurate diagnosis and treatment. The company specializes in analyzing laboratory data to help doctors and pharmaceutical companies identify the specific tests needed for treating individual patients. It also offers a variety of services to optimize the use of tests in patient care. Diaceutics operates in three divisions: Diagnostic Services, Data and Analytics Services, and Strategy and Implementation Services. Diagnostic Services include optimizing diagnostic tests and identifying patient populations that would benefit from a particular treatment. Data and Analytics Services involve setting up data and analytics platforms to gain insights into the use of diagnostic tests in clinical practice. Strategy and Implementation Services support pharmaceutical companies in conducting campaigns to promote the use of diagnostic tests and increase the availability of personalized medicines. Diaceutics' products and services also include Diagnostic Insights products, providing insights into the use of diagnostic tests in various therapy areas. These insights help pharmaceutical companies optimize their personalization strategies and enhance the effectiveness of their medicines. The company also offers diagnostic programs aimed at promoting the use of diagnostic tests in clinical practice and eliminating barriers to the use of personalized medicines. Diaceutics has established partnerships with many of the world's leading diagnostic and pharmaceutical companies and also provides consulting services to support them in developing personalization strategies. Its clients include both pharmaceutical and diagnostic companies. Overall, Diaceutics has become a leading provider of personalized healthcare solutions. It occupies a unique position in the market by focusing on the intersection of diagnostics and therapy and being able to offer a wide range of products and services. Given the rapid progress in personalized medicine, Diaceutics will continue to play a significant role in optimizing diagnosis and treatment strategies and providing better care for patients. Diaceutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Diaceutics's Shares Outstanding
Diaceutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Diaceutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Diaceutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Diaceutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Diaceutics stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Diaceutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Diaceutics evolved in recent years?
The number of shares of Diaceutics has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Diaceutics as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Diaceutics?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Diaceutics pay?
Over the past 12 months, Diaceutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Diaceutics is expected to pay a dividend of 0 GBP.
What is the dividend yield of Diaceutics?
The current dividend yield of Diaceutics is .
When does Diaceutics pay dividends?
Diaceutics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Diaceutics?
Diaceutics paid dividends every year for the past 0 years.
What is the dividend of Diaceutics?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is Diaceutics located?
Diaceutics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Diaceutics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Diaceutics from 10/19/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 10/19/2024.
When did Diaceutics pay the last dividend?
The last dividend was paid out on 10/19/2024.
What was the dividend of Diaceutics in the year 2023?
In the year 2023, Diaceutics distributed 0 GBP as dividends.
In which currency does Diaceutics pay out the dividend?
The dividends of Diaceutics are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Diaceutics
Our stock analysis for Diaceutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Diaceutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
